Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index; 12 of the 168 sources its claims cite were checked for support.
Abstract
Purpose of Review: Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD. The failure could be attributed to their low selectivity and potency for binding to peroxisome proliferator-activated receptor (PPAR) α. To resolve these issues, the concept of selective PPARα modulator (SPPARMα) with a superior balance of efficacy and safety has been proposed and pemafibrate (K-877) has been developed. Recent Findings: Pemafibrate, one of SPPARMsα, was synthesized by Kowa Company, Ltd. for better efficiency and safety. Clinical trials in Japan have established the superiority of pemafibrate on effects on serum triglycerides (TG) reduction and HDL-C elevation as well safety. Although available fibrates showed worsening of liver and kidney function test values, pemafibrate indicated improved liver function test values and was less likely to increase serum creatinine or decrease estimated glomerular filtration rate (eGFR). Very few drug-drug interactions were observed even when used concomitantly with statins. Furthermore, pemafibrate is metabolized in the liver and excreted into the bile, while many of available fibrates are mainly excreted from the kidney. Therefore, pemafibrate can be used safely even in patients with impaired renal function since there is no significant increase in its blood concentration. A large-scale trial of pemafibrate, PROMINENT, for dyslipidemic patients with type 2 diabetes is ongoing. Summary: Pemafibrate is one of novel SPPARMsα and has superior benefit-risk balance compared to conventional fibrates and can be applicable for patients for whom the usage of existing fibrates is difficult such as those who are taking statins or patients with renal dysfunction. In the current review, all the recent data on pemafibrate will be summarized.
Overview
CoChat Summary
TL;DR
Pemafibrate (K-877) is the first selective PPARα modulator (SPPARMα), designed to retain the triglyceride-lowering and HDL-C-raising effects of fibrates while avoiding their off-target liver, kidney, and drug-interaction liabilities. This narrative review summarizes its pharmacology, preclinical data, and Japanese clinical trial program, and notes that the cardiovascular outcome trial PROMINENT is still ongoing.
Key findings
- Pemafibrate's PPARα activation is >2500 times stronger than fenofibric acid, with subtype selectivity >5000-fold for PPARγ and >11,000-fold for PPARδ.
- In clinical trials, pemafibrate 0.4 mg/day lowered TG by ~42.7% (vs 29.7% for fenofibrate 100 mg/day) and raised HDL-C by ~21.0% (vs 14.3%), with effects comparable to fenofibrate 200 mg/day; it reduced ALT, γ-GT, and ALP by ~8 U/L, ~24 U/L, and ~70–80 U/L respectively, whereas fenofibrate worsened these values.
- Co-administered with pitavastatin, pemafibrate reduced fasting TG by 46.1% (0.1 mg/day), 53.4% (0.2 mg/day), and 52.0% (0.4 mg/day) versus 6.9% for placebo, with no major drug–drug interaction with statins.
- Pemafibrate is mainly hepatically metabolized with only 14.5% urinary excretion and <0.5% unmetabolized drug in urine, so exposure does not increase with renal dysfunction; a meta-analysis found total adverse events significantly lower than with fenofibrate, though LDL-C was significantly higher in the pemafibrate group.
Methods
- Narrative review synthesizing preclinical (cell, rodent, pig) and clinical data on pemafibrate, including its development, pharmacokinetics, and mechanism as a SPPARMα.
- Draws on Japanese phase 2/3 randomized controlled trials (K-877-04, -09, -11, -17, -19), a meta-analysis comparing pemafibrate with fenofibrate, and animal models of dyslipidemia, atherosclerosis, NASH, and obesity.
- Summarizes comparative tables of percentage changes in lipid, glycemic, liver, and renal parameters for pemafibrate versus fenofibrate.
Limitations
- As stated by the paper: the cardiovascular benefit of pemafibrate in humans is not yet established—the large-scale PROMINENT trial (planned 10,000 patients with type 2 diabetes, high TG, low HDL-C, across 24 countries) is still ongoing.
- As stated by the paper: pemafibrate was not administered to patients with extremely high TG (>1000 mg/dL) in developmental studies, and its effect in severe hypertriglyceridemia remains to be explored; the PBC evidence comes from a small pilot study.
- Evident from the text: this is a narrative review without primary data or systematic search methodology, and much of the clinical evidence derives from Japanese trials, limiting generalizability to other populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Structural differences in the interaction of pemafibrate and fenofibrate with PPARα and the concept of SPPARMα. The binding affinity of pemafibrate to PPARα is markedly increased compared with that of fenofibrate because pemafibrate has many interaction sites in regions A, B, and C of PPARα. The specific binding of pemafibrate with a high affinity results in specific conformational transitions of PPARα, recruiting specific co-activator complexes. Thus, pemafibrate has specific effects on target genes, but not off-target genes. In contrast, fenofibrate has specific effects on target as well as off-target genes. Reproduced from ref [47••]. Partially modified from refs [43] and [48]](https://figures.cochat.ai/paper-figures/76da9514a57e40d9a284446dc81859b4/pemafibrate-a-new-selective-ppar-modulator-drug-concept-and-its-clinical-figure-1.jpg)


Verification
Claims the paper makes
10 Valid · 1 Not valid · 120 Not checked · 29 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD).”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Abstract > Purpose of Review
What the sources say
- Partly supportedcites [67] Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009;16(3):145–54. sourceExperimental — accuracy not yet measured
Our copy supports the lipid components of the claim: the Introduction and Abstract state that hypertriglyceridemia is associated with atherosclerosis independent of other coronary risk factors, the 'Postprandial Hyperlipidemia as the Atherogenic Condition' section reports a relationship between postprandial hyperlipidemia and atherosclerotic disease (especially CAD) and the atherogenicity of fasting RLP-C, and 'Effects on Other Lipoproteins' includes low HDL-C in the atherogenic lipid profile. However, no passage frames these as RESIDUAL risk persisting AFTER LDL-C lowering: the paper's LDL-C comparison is only that triglycerides alone are hard to use for risk selection 'compared with LDL-C', and it never discusses patients treated to lower LDL-C or leftover risk. The residual-risk/after-LDL-lowering part of the attributed claim is therefore not supported by this source. (LLM, conf=0.70)
- Supportedcites [68] Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24(2):95–109. source
The opening of the 'Fasting and Postprandial Hypertriglyceridemia' section states that statin-based intensive intervention against hypercholesterolemia/hyper LDL-cholesterolemia improves primary and secondary prevention of CHD events but has not completely suppressed them, and that controlling 'residual risk factors' — hypertriglyceridemia (≥150 mg/dL) and hypo-HDL-cholesterolemia (<40 mg/dL) — has been emphasized for the prevention of ASCVD. The Abstract and the same section further establish that both fasting hypertriglyceridemia (meta-analysis of 35 observational studies; risk on a background of statin treatment after ACS) and postprandial/non-fasting hypertriglyceridemia (Iso et al., Nordestgaard et al.) are associated with CHD/ASCVD risk, covering every element of the paraphrase. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, fibrates were demonstrated to cause side effects such as liver dysfunction and increase in creatinine levels, and thus large-scale clinical trials of fibrates have shown negative results for prevention of ASCVD.”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Abstract > Purpose of Review
What the sources say
- Not checked yetcites [7] Bezafibrate Infarction Prevention (BIP) Study Group, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102(1):21–7. source
- Not checked yetcites [8] Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. source
- Partly supportedcites [9] Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. sourceExperimental — accuracy not yet measured
Our copy of ACCORD Lipid supports the general direction only in part: the Abstract (RESULTS) and Results (Clinical Outcomes) report that adding fenofibrate to simvastatin in 5518 patients with type 2 diabetes gave no significant difference in the primary composite of nonfatal MI, nonfatal stroke or cardiovascular death (HR 0.92; 95% CI 0.79–1.08; P = 0.32) — a null, not a harmful, result, and confined to a diabetic, statin-treated population rather than ASCVD prevention generally. The Introduction (Abstract) and Discussion explicitly qualify any blanket 'negative trials' reading: fibrate therapy 'reduced the rate of coronary heart disease events in VA-HIT but not in the FIELD trial', a post hoc FIELD analysis suggested benefit with high triglycerides/low HDL, and the Discussion states the subgroup results 'support the view that the addition of fenofibrate to a statin may benefit patients with type 2 diabetes who have substantial dyslipidemia'. Nothing in our copy links the trial outcome to adverse effects: the Safety section reports only modest ALT elevations (1.9% vs 1.5%) and rises in serum creatinine, and states 'No evidence for such a risk [myositis or rhabdomyolysis] was noted in our study', so the citing sentence's causal framing ('cause side effects ... and thus ... negative results') is not attributable to this source. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Therefore, SPPARMα may have a better benefit-risk balance compared to the PPARα agonists such as available fibrates.”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Introduction > Development of a Novel SPPARMα, Pemafibrate
What the sources say
- Supportedcites [43] Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol. 2013;12:82. source
The Conclusions state that fibrates are weak PPARα agonists with limited efficacy due to dose-related AEs, and that the SPPARMαs are a new generation being developed to 'separate the receptor-mediated beneficial effects of the PPARα agonists from their unwanted side effects' — i.e. an improved benefit-risk profile. The Abstract and Conclusions apply this to the first true SPPARMα, K-877, which 'compared to fenofibrate has more potent PPARα-activating efficacy in vitro, greater effects on triglycerides- and HDL-C levels in humans, and a reduced risk of adverse effects' and 'an improved safety/tolerability profile', with the potential to supersede fibrates. The citing sentence is hedged ('may'), matching the paper's own conditional framing ('If successful…'), so the paraphrase is supported. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In the Helsinki Heart Study (HHS) [4] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) [5], administration of gemfibrozil significantly reduced CV event rate, the primary endpoints of the trials.”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Introduction
What the sources say
- Not checked yetcites [4] Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45. source
- Supportedcites [5] Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8. source
For the part attributed to this source (VA-HIT, reference [5]), our copy states the trial's primary outcome (nonfatal MI or death from coronary causes) occurred in 21.7% of placebo vs 17.3% of gemfibrozil patients, a 22% relative risk reduction (95% CI 7–35, P=0.006) — Outcomes p. 8 and Abstract. The Abstract/Conclusion (p. 4) further states 'Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level.' The Helsinki Heart Study clause belongs to the separate citation [4] and is not judged here. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Calculated insulinogenic index was significantly lower in patients with Tangier disease than in non-diabetic controls.”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Introduction > Other Non-lipid-Related Effects of Pemafibrate
What the sources say
- Supportedcites [98] Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb. 2009;16(3):292–6. source
The Abstract reports that the calculated insulinogenic index was significantly lower in four Tangier disease patients than in non-diabetic controls (0.055±0.034 versus 0.775±0.538; p<0.05). The Oral Glucose Tolerance Test section also reports a marked decrease compared with normal subjects. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
86 more claims
Create a free account to see all 160 claims and to verify the 156 references still open.
- It may state two separate claims as one. 67
- Probably not a substantial claim. 5
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is a new selective peroxisome proliferator-activated receptor-α modulator with a superior benefit-risk balance compared with conventional fibrates.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > Introduction > Clinical Trials of Pemafibrate
“In SHARP trial [90], non-statin drug ezetimibe (intestinal cholesterol transporter inhibitor) showed a significant reduction in CV events.”
§ Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases > References
“90. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes.”
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Research works printed but not linked: 3
- Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E, et al. The novel PPARα selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e86–93 (Abstract 24160).
- Iwata H, Murakami K, Ricchiuto P, Singh S, Libby P, Aikawa E, et al. The novel PPARα selective agonist K-877 suppresses pro-inflammatory pathways and experimental arterial lesion formation. Circ Res. 2014;115:e90 [AHA2014 Abstract].
- Takizawa T, Goto S, Inokuchi Y, Miyata S, Yoshinaka Y, Yamazaki H, et al. Pharmacological effects of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha)-Controlling the plasma HDL-C and triglycerides, and prevention of atherosclerosis in experimental animals. Eur Heart J. 2015;36:257–8 [ESC2015 Abstract].
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R., & Sanyal, A. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 168
“Pemafibrate is a highly selective PPAR-α agonist that promotes the induction of genes involved in fatty acid oxidation, lipid mobilization and energy metabolism.(116,117) In a clinical trial in patients with”
BackgroundImpact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Wang, L., Cai, Y., Jian, L., Cheung, C. W., Zhang, L., & Xia, Z. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01188-0 · Cited by 120
“PPARα-related drugs that might be safe in treating DCM Different from conventional fibrates, pemafibrate (K-877, ParmodiaTM), a novel selective PPARα modulator, is mainly metabolized by the liver [150, 151], and is 2500 times effective in activating PPARα than the conventional fibrates [41, 150] and having a better tr…”
Background
Metadata
- Authors
- Yamashita, S., Masuda, D., & Matsuzawa, Y.
- Affiliations
- Rinku General Medical Center (JP)
- Corresponding author
- Yamashita, Shizuya
- Venue
- Current Atherosclerosis Reports
- Published
- 2020-01
- Volume
- 22
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- PMC
- PMC6978439
- OpenAlex
- W3002287592
- Cited by
- 191
- References
- 124
- Citations by year
- 2026: 21 · 2025: 35 · 2024: 29 · 2023: 40 · 2022: 30 · 2021: 24 · 2020: 12
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 22 d)
- Locations
- Current Atherosclerosis Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Kowa Company
- Japan Society for the Promotion of Science (17H02100)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- pemafibrate, PPARα, hypertriglyceridemia, dyslipidemia, HDL cholesterol, LDL cholesterol, atherosclerotic cardiovascular disease, type 2 diabetes, drug-drug interactions, renal safety, liver safety, fibrates, statins, PCSK9 inhibitors, drug metabolism, drug repurposing
- MeSH terms
- Animals, Hypolipidemic Agents, Benzoxazoles, Butyrates, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Cholesterol, HDL, Fenofibrate, Triglycerides, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. https://app.cochat.ai/papers/10.1007/s11883-020-0823-5
- The paper
- Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020). Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-020-0823-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.